CDC grant supports National Blood Clot Alliance’s COVID-19 research and public awareness campaign


NEW YORK, July 28, 2020 / PRNewswire / – The National Blood Clot Alliance (NBCA –, the country’s leading patient advocacy organization focused on life-threatening blood clots, in partnership with the University of Oklahoma, received an award as part of an Association of University Centers on Disabilities-Centers for Disease Control cooperative agreement to facilitate and advance research into blood clots as a complication of COVID-19. The award will also fund researchers’ efforts to educate certain high-risk populations, including how complications from COVID blood clots affect African Americans and pediatric patients.

Already responsible for more deaths each year in the United States than breast cancer, AIDS and traffic accidents combined, blood clots have been commonly seen in patients hospitalized with COVID-19 since the start of the pandemic. The disease is often characterized by elevations in fibrinogen and D-dimer levels as well as clinical events including deep vein thrombosis (DVT), pulmonary embolism (PE) and arterial events including stroke . However, little is known about the incidence, prevalence and outcome of COVID-related blood clots in adult and pediatric patients.

NBCA Medical and Scientific Advisory Board (MASAB) hopes to fill this knowledge gap by merging data collected across the United States into a central repository of information on COVID-linked blood clots so that experts can begin to refine the most effective and best treatment regimens practice.

“As the complex clinical impacts of this global pandemic continue to emerge, medical experts in hematology and blood disorders continue to refine their understanding of the link between COVID-19 and potentially fatal blood clots,” says Alok Khorana, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine and NBCA MASAB Chair. “Therefore, it is crucial that the collective knowledge and ideas of experts in this field are harnessed effectively to strengthen the work of our frontline clinicians to help optimize care for all patients affected by COVID-19. “

Globally, more than 16 million people have been infected with the novel coronavirus to date, and more than 600,000 have died from COVID-19, as medical experts in the field are increasingly concerned about the data suggests about one in three people seriously ill with COVID-19 will develop a life-threatening blood clot. Equally concerning are reports that patients with milder illness, or even those who are asymptomatic or unaware they are infected with the coronavirus, develop dangerous blood clots.

“The National Blood Clot Alliance is strongly committed to ensuring that the highest quality standards of care are recognized by clinicians and accessible to all people affected by bleeding disorders, including unprecedented coagulation reported in patients. people affected by COVID-19, or anyone who could experience a potentially fatal blood clot, ”emphasizes Leslie Lake, chairman of the board of directors of the NBCA and survivor of a blood clot. “The blood disorder community needs to combine its resources and expertise to lessen the impact of blood clots and help educate physicians and patients.”

The main objectives of the NBCA in this work include:

  • Development of the COVID-19 blood clot data repository – Development of an online data repository to collect and analyze information concerning the prevalence of venous and arterial thromboembolic events in adult and pediatric hospital settings, in intensive care and after hospital discharge
  • Review of African American and Pediatric High-Risk Populations – Collect and disseminate rates of thromboembolic events among less studied populations, including African Americans and children
  • Establishment of best treatment practices – Plan and organize a survey on best practices regarding treatments for blood clots for hospitalized patients with COVID-19, intensive care patients with COVID-19 and adult and pediatric patients discharged after hospitalization for COVID- 19
  • Train clinicians and health professionals – Develop a narrative and / or systematic review that analyzes and interprets data from the above-mentioned surveys as well as contributions from patients and patient advocates to educate healthcare professionals on the prevalence of COVID-related blood clots- 19, incidence and best practices for anticoagulants

Another essential element of the grant program is the development of a public awareness campaign to provide new knowledge and information on the association between COVID-19 and the development of blood clots to populations at higher risk, to the general public. and health professionals through easily made educational materials. available online.

For more information on risk factors and signs and symptoms of blood clots, visit the NBCA website at

SOURCE National Blood Clot Alliance

Related links

Source link

Leave A Reply

Your email address will not be published.